Lefere, Sander <br/><br/>
Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges.  [electronic resource] 

 -  Expert opinion on investigational drugs  Feb 2020 
 - 89-92 p.  digital 
<br/><br/> Publication Type: Editorial 
<br/><br/><label>ISSN: </label>1744-7658 
<br/><br/><label>Standard No.: </label>10.1080/13543784.2020.1718106  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>CCR5 Receptor Antagonists--pharmacology<br/>Drug Development<br/>Humans<br/>Liver Cirrhosis--drug therapy<br/>Non-alcoholic Fatty Liver Disease--drug therapy<br/>Receptors, CCR2--antagonists & inhibitors<br/>Receptors, CCR5--drug effects